Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Summary
Adcytherix closed a EUR 105 million Series A to push its antibody-drug conjugate pipeline forward. The company will use the capital to advance ADCX-020 into the clinic and file IND and CTA applications by the end of 2025. It will also expand development of additional proprietary ADC programs built around novel payloads. The round brought in a large syndicate of new and existing investors, reinforcing the company’s position in the ADC space.
Funding
Amount
$122.0M
Total raised
Date
October 16, 2025
Announcement date
Investors
Kurma Life Science Partners, Edmond de Rothschild, Pureos Bioventures, Bpifrance SME Accelerator, RA Capital Management, Citadel, Pontifax
Lead investors
Company
adcytherix.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected